Glucotrack prices $3 million public offering of stock and pre-funded warrants

Glucotrack, Inc. (NASDAQ: GCTK) announced on September 24, 2026 the pricing of a "best efforts" public offering. The offering consists of 169,388 shares of common stock at a price of $2.04 per share and, in lieu of shares to certain investors, pre-funded warrants to purchase up to 1,350,220 shares of common stock at a price of $2.039 per pre-funded warrant.¹ The company expects to receive aggregate gross proceeds of approximately $3,100,000, before deducting placement agent fees and offering expenses.¹ The offering was priced at-the-market under Nasdaq rules and is expected to close on or about September 25, 2026, subject to customary closing conditions.¹

Dawson James Securities, Inc. is acting as the sole placement agent for the offering.¹ Under the placement agency agreement, Glucotrack agreed to pay Dawson James a cash fee equal to 8.0% of gross proceeds received from sales the agent arranged.¹

The company said it expects to use the net proceeds from the offering to pay off existing debt, with the remainder used for working capital and general corporate purposes.¹

This offering follows other recent capital raises. On August 4, 2026, Glucotrack closed an Interim PIPE for gross proceeds of $2,000,000, and on September 10, 2026 the company entered a separate financing of senior secured convertible promissory notes with an aggregate principal amount of $11,596,172.68, reflecting approximately $4.5 million of new cash investment and approximately $4.5 million of existing notes being rolled over, with the aggregate principal amount reflecting a 22% original issue discount,² generating $4,500,000 in actual gross cash proceeds to the company.

In connection with the current offering, the company's directors and executive officers entered into 90-day lock-up agreements restricting sales of company stock.¹